These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7963690)

  • 41. Hammerhead ribozymes: biochemical and chemical considerations.
    Goodchild J
    Curr Opin Mol Ther; 2000 Jun; 2(3):272-81. PubMed ID: 11249621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).
    Sioud M
    Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The therapeutic potential of ribozymes.
    James HA; Gibson I
    Blood; 1998 Jan; 91(2):371-82. PubMed ID: 9427689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo.
    Taylor NR; Kaplan BE; Swiderski P; Li H; Rossi JJ
    Nucleic Acids Res; 1992 Sep; 20(17):4559-65. PubMed ID: 1408757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ribozyme gene therapy: applications for molecular medicine.
    Lewin AS; Hauswirth WW
    Trends Mol Med; 2001 May; 7(5):221-8. PubMed ID: 11325634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Substitution of non-catalytic stem and loop regions of hammerhead ribozyme with DNA counterparts only increases KM without sacrificing the catalytic step (kcat): a way to improve substrate-specificity.
    Shimayama T; Sawata S; Komiyama M; Takagi Y; Tanaka Y; Wada A; Sugimoto N; Rossi JJ; Nishikawa F; Nishikawa S
    Nucleic Acids Symp Ser; 1992; (27):17-8. PubMed ID: 1283905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.
    O'Neill B; Millington-Ward S; O'Reilly M; Tuohy G; Kiang AS; Kenna PF; Humphries P; Farrar GJ
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2863-9. PubMed ID: 10967039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint.
    Flory CM; Pavco PA; Jarvis TC; Lesch ME; Wincott FE; Beigelman L; Hunt SW; Schrier DJ
    Proc Natl Acad Sci U S A; 1996 Jan; 93(2):754-8. PubMed ID: 8570629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ribozymes as antiviral agents.
    Bartolomé J; Castillo I; Carreño V
    Minerva Med; 2004 Feb; 95(1):11-24. PubMed ID: 15041923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV and Ribozymes.
    Scarborough RJ; Gatignol A
    Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ribozymes: structure, characteristics and use as potential antiviral agents.
    Bartolomé J; Madejón A; Carreño V
    J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity.
    Sioud M
    J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
    Li YL; Torchet C; Vergne J; Maurel MC
    Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.
    Bramlage B; Luzi E; Eckstein F
    Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hairpin ribozyme-mediated cleavage of the full-length beta-glucuronidase (GUS) mRNA.
    Hisamatsu S; Sonoki S; Kikuchi Y
    Biosci Biotechnol Biochem; 1995 Feb; 59(2):294-7. PubMed ID: 7766027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism of action of hammerhead ribozymes and their applications in vivo: rapid identification of functional genes in the post-genome era by novel hybrid ribozyme libraries.
    Takagi Y; Suyama E; Kawasaki H; Miyagishi M; Taira K
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1145-9. PubMed ID: 12440992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ribozymes: structure, function, and potential therapy for dominant genetic disorders.
    Grassi G; Marini JC
    Ann Med; 1996 Dec; 28(6):499-510. PubMed ID: 9017109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ribozymes in gene therapy of HIV-1.
    Macpherson JL; Ely JA; Sun LQ; Symonds GP
    Front Biosci; 1999 Jun; 4():D497-505. PubMed ID: 10352136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiviral and anticancer ribozymes.
    Poeschla E; Wong-Staal F
    Curr Opin Oncol; 1994 Nov; 6(6):601-6. PubMed ID: 7827172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.